Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerispirdine placebo-controlled phase 2 trial in multiple sclerosis
2008-001999-67Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nerispirdine in multiple sclerosis (MS) (4 arms), sponsored by Sanofi. Primary endpoint: Responder criterion based on consistent improvement in walking speed on the Timed 25-Foot Walk. Started Nov 2008; status: completed.
02
Drugs
nerispirdine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-001999-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001999-67.